Business Context and Reporting Period
Company: InspireMD, Inc. (NSPR)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: InspireMD is a medical device company specializing in carotid artery disease treatment. Its portfolio includes the CGuard EPS (marketed internationally via distributors) and CGuard Prime (marketed in the U.S. via direct sales). In June 2025, the company received FDA Premarket Approval (PMA) for CGuard Prime and launched commercial sales in the U.S. in July 2025. The company also received CE Mark approval for CGuard Prime under the EU MDR in June 2025.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $8.98 million | $7.01 million |
| Gross Profit | $2.65 million | $1.51 million |
| Gross Margin | 29.5% | 21.5% |
| Net Loss | $(48.79) million | $(32.01) million |
| Operating Cash Flow | $(35.10) million | $(21.87) million |
| Cash & Cash Equivalents | $8.94 million | $18.92 million |
| Marketable Securities | $45.27 million | $15.72 million |
| Total Assets | $69.40 million | $46.81 million |
| Accumulated Deficit | $(302.29) million | $(253.51) million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 28.1% to $8.98 million, driven by the U.S. commercial launch of CGuard Prime ($1.39 million increase in North America) and continued international growth of CGuard EPS.
- Margin Expansion: Gross margin improved by 8.0 percentage points to 29.5%, attributed to a favorable revenue mix from higher-margin direct U.S. sales compared to international distributor sales.
- Expense Increases:
- Selling & Marketing: Increased 172.7% to $16.55 million due to building the U.S. direct sales force.
- General & Administrative: Increased 35.3% to $20.71 million due to new hires and occupancy costs for the new Miami headquarters.
- R&D: Increased 10.0% to $15.00 million, driven by clinical expenses for SwitchGuard NPS and CGuard Prime 80 cm.
- Liquidity Position: While cash and cash equivalents decreased to $8.94 million, total liquid assets (including marketable securities) increased to $54.21 million. The company raised approximately $55.6 million in financing activities during 2025, including a $40.1 million private placement and warrant exercises.
Guidance, Outlook, Risks, and Contingencies
- Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern. The company does not have sufficient resources to fund operations for the next 12 months without additional financing. The independent auditor's report includes an explanatory paragraph regarding this uncertainty.
- Capital Needs: The company expects to incur additional losses and requires further capital to fund U.S. commercialization, manufacturing expansion, and ongoing clinical trials (CGUARDIANS II and III).
- Outlook: The company is transitioning to a commercial-stage entity in the U.S. Future success depends on market acceptance of CGuard Prime, reimbursement levels, and the ability to scale manufacturing (currently transitioning to a contract manufacturer in North Carolina).
- Key Risks:
- Geopolitical: Manufacturing is currently based in Israel. Ongoing regional conflicts (Israel, Gaza, Lebanon, Iran) pose risks to operations, supply chain, and personnel safety.
- Regulatory: Future approvals for SwitchGuard NPS and expanded indications (TCAR) are required for full market potential. Failure to meet IDE requirements could delay commercialization.
- Supply Chain: Reliance on single-source suppliers for critical components (e.g., PET resin for MicroNet mesh). Validation of alternative sources is ongoing.
- Competition: Intense competition from larger, well-capitalized medical device companies (e.g., Abbott, Boston Scientific, Medtronic).
Investor Verification Checklist
- Capital Runway: Verify the timeline and terms of any new financing required to bridge the gap before the company achieves profitability, given the "substantial doubt" going concern warning.
- U.S. Sales Trajectory: Monitor quarterly revenue from the U.S. direct sales channel to assess the success of the CGuard Prime commercial launch and market penetration.
- Manufacturing Transition: Confirm the status of the production transfer to the Aptyx facility in North Carolina to mitigate reliance on Israeli manufacturing amidst geopolitical instability.
- Clinical Trial Milestones: Track enrollment and results of the CGUARDIANS II (TCAR) and CGUARDIANS III (SwitchGuard) trials, as these are critical for future revenue growth and warrant exercises.
- Warrant Exercises: Review the status of remaining Series J and Series K warrants, which are tied to specific regulatory and commercial milestones and represent potential future dilution or capital inflow.